{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:35:34Z","timestamp":1745469334055,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s43441-025-00749-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T18:28:38Z","timestamp":1740594518000},"page":"489-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Data Monitoring Experience in Empagliflozin Randomized Clinical Trials Between 2011 and 2024"],"prefix":"10.1007","volume":"59","author":[{"given":"Francine K.","family":"Welty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Konstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Daher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154\u201360. https:\/\/doi.org\/10.1111\/dom.12185.","journal-title":"Diabetes Obes Metab"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type1 diabetes: the EASE trials. Diabetes Care. 2018;41:2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"key":"749_CR4","doi-asserted-by":"publisher","unstructured":"Laffel LM, Danne T, Klingensmith GJ, et al, on behalf of the DINAMO Study Group. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11:169\u2013181. https:\/\/doi.org\/10.1016\/S2213-8587(22)00387-4","DOI":"10.1016\/S2213-8587(22)00387-4"},{"key":"749_CR5","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, G. Filippatos G, et al. for the EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"749_CR6","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, J. Butler J, et al. for the EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42:700\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa943.","journal-title":"Eur Heart J"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390:1455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2314051.","journal-title":"N Engl J Med"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJM199805073381911","volume":"338","author":"CL Meinert","year":"1998","unstructured":"Meinert CL. Masked monitoring in clinical trials\u2014blind stupidity? N Engl J Med. 1998;338:1381\u20132. https:\/\/doi.org\/10.1056\/NEJM199805073381911.","journal-title":"N Engl J Med"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1740774516688915","volume":"14","author":"TR Fleming","year":"2017","unstructured":"Fleming TR, DeMets DL, Roe MT, et al. Data monitoring committees: promoting best practices to address emerging challenges. Clin Trials. 2017;14:115\u201323. https:\/\/doi.org\/10.1177\/1740774516688915.","journal-title":"Clin Trials"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ahj.2004.10.038","volume":"149","author":"S Pocock","year":"2005","unstructured":"Pocock S, Wang D, Wilhelmsen L, Hennekens CH. The data monitoring experience in the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2005;149:939\u201343. https:\/\/doi.org\/10.1016\/j.ahj.2004.10.038.","journal-title":"Am Heart J"},{"key":"749_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022537","author":"S Kaul","year":"2016","unstructured":"Kaul S. Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true? Circulation. 2016. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022537.","journal-title":"Circulation"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/s0197-2456(97)00075-5","volume":"18","author":"RT O\u2019Neill","year":"1997","unstructured":"O\u2019Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials. 1997;18:550\u20136. https:\/\/doi.org\/10.1016\/s0197-2456(97)00075-5.","journal-title":"Control Clin Trials"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMra1510064","volume":"275","author":"SJ Pocock","year":"2016","unstructured":"Pocock SJ, Stone GW. The primary outcome fails\u2014what next? N Engl J Med. 2016;275:861\u201370. https:\/\/doi.org\/10.1056\/NEJMra1510064.","journal-title":"N Engl J Med"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/biomet\/43.3-4.461","volume":"43","author":"FJ Anscombe","year":"1956","unstructured":"Anscombe FJ. On estimating binomial response relations. Biometrika. 1956;43:461\u20134. https:\/\/doi.org\/10.1093\/biomet\/43.3-4.461.","journal-title":"Biometrika"},{"issue":"4","key":"749_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/2168479017739268","volume":"52","author":"KA Buhr","year":"2018","unstructured":"Buhr KA, Downs M, Rhorer J, Bechhofer R, Wittes J. Reports to independent data monitoring committees: an appeal for clarity, completeness, and comprehensibility. Ther Innov Regul Sci. 2018;52(4):459\u201368. https:\/\/doi.org\/10.1177\/2168479017739268.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"749_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/CRD.0000000000000422","volume":"30","author":"FK Welty","year":"2022","unstructured":"Welty FK, Rajai N, Amangurbanova M. Comprehensive review of cardiovascular complications of coronavirus disease 2019 and beneficial treatments. Cardiol Rev. 2022;30(3):145\u201357. https:\/\/doi.org\/10.1097\/CRD.0000000000000422.","journal-title":"Cardiol Rev"},{"key":"749_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2018. Vienna, Austria"},{"key":"749_CR20","doi-asserted-by":"publisher","DOI":"10.1201\/9781138359444","volume-title":"R markdown: the definitive guide","author":"Y Xie","year":"2018","unstructured":"Xie Y, Allaire J, Grolemund G. R markdown: the definitive guide. Boca Raton: Chapman and Hall\/CRC; 2018."},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa13137","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa13137.","journal-title":"N Engl J Med"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00749-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:50:52Z","timestamp":1745434252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00749-3","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors except Dr. Daher are a consultant to Boehringer Ingelheim as member of the Data Monitoring Committee described in this manuscript. The DMC members report no other conflicts related to the content of this manuscript. Dr. Daher reports no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}